Versant Ventures VI GP, L.P., 10% Owner at Akero Therapeutics, Inc. (AKRO), sold 106,114 shares at $20.05 ($2.1M) on 2020-01-07, disclosed to the SEC on 2020-07-10.
Scheduled sale ($2.1M) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.05 | 14,162 | $284K | 13.4% |
| 2 | $20.05 | 14,162 | $284K | 13.4% |
| 3 | $19.80 | 22,368 | $443K | 20.9% |
| 4 | $19.80 | 22,368 | $443K | 20.9% |
| 5 | $20.21 | 16,527 | $334K | 15.7% |
| 6 | $20.21 | 16,527 |
| $334K |
| 15.7% |
| Total | $19.99 avg | 106,114 | $2.1M | 100% |
| Filing → |
| GLUE | BUY | 2021-06-30 | $3.0M | — | Filing → |
| PASG | BUY | 2020-03-03 | $4.0M | — | Filing → |